Acceptability of cannabidiol as a treatment for people at clinical high risk for psychosis
Abstract Background: At present, there are no approved pharmacological treatments for people at clinical high risk for psychosis (CHR-P). We…
Amedeo Minichino
Novel Lipid Formulation Increases Absorption of Oral Cannabidiol (CBD)
Abstract Background: Cannabidiol (CBD) is an approved treatment for childhood epilepsies and a candidate treatment for several other CNS disorders.…
Effects of Cannabidiol and Delta-9-Tetrahydrocannabinol on Plasma Endocannabinoid Levels in Healthy Volunteers: A Randomized Double-Blind Four-Arm Crossover Study
Abstract Background: The effects of cannabis are thought to be mediated by interactions between its constituents and the endocannabinoid system.…
Endocannabinoid system mediates the association between gut-microbial diversity and anhedonia/amotivation in a general population cohort
Abstract Anhedonia and amotivation are debilitating symptoms and represent unmet therapeutic needs in a range of clinical conditions. The gut-microbiome-endocannabinoid…